• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops and markets biosurgical and immunotherapy products derived from human plasma. The company offers a fibrin sealant, used as an adjunct to hemostasis in liver surgery as Evicel in the United States, and as Quixil, used as an adjunct to hemostasis for general surgical use in Germany, the United Kingdom, France, Italy, Brazil, and Mexico, as well as an adjunct to hemostasis in liver and orthopedic surgeries in various European Union countries and Israel. The company's biosurgical products under development include Evicel for use as an adjunct to hemostasis for general surgeries in the United States and the European Union; Fibrin Patch, which is under Phase I clinical trials for the management and control of bleeding, including severe or brisk bleeding, and for use on active bleeding sites. Its developing product portfolio includes Thrombin, which completed Phase III clinical trials for use as an adjunct to hemostasis for general surgeries, primarily for use in neurosurgery in the U.S.; and Adhexil, an investigational new drug for prevention and reduction of post-operative adhesions in patients undergoing pelvic surgery. It also markets immunotherapy products, including VIG to treat smallpox vaccine-related complications under government contracts; IVIG primarily for the treatment of patients with immune deficiency; and HBIG for the prevention of reinfection of transplanted livers with HBV in Israel. The company's immunotherapy products under development include HT-VIG for treatment and prevention of side effects of vaccination against smallpox; WNIG/HT-WNIG to treat severe infection with the West Nile virus, which completed enrollment for Phase I/II clinical trial in the U.S.; and Avian Influenza IG for the treatment of avian influenza.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
TAUB ROBERT CHIEF EXECUTIVE OFFICER |
|
2,837,103 | 2008-11-23 | 0 |
|
ALPEROVITZ ASAF CHIEF FINANCIAL OFFICER |
|
300 | 2008-10-23 | 0 |
|
MASHIACH NISSIM PRESIDENT AND COO |
|
27,000 | 2008-10-10 | 0 |
|
6,000 | 2008-09-04 | 0 | |
|
5,000 | 2008-09-04 | 0 | |
|
4,000 | 2008-09-04 | 0 | |
|
10,467 | 2008-09-04 | 0 | |
|
119,627 | 2008-09-04 | 0 | |
|
MCNAMARA PAMELA W |
|
0 | 2008-05-15 | 0 |
|
DROPPERT V. MARC EXECUTIVE VICE PRESIDENT |
|
4,000 | 2008-03-18 | 0 |
|
No longer subject to file | 2008-02-28 | 0 | |
|
PRADO NANCI GENERAL COUNSEL |
|
27,000 | 2007-11-08 | 0 |
|
STANCIC ANA CHIEF FINANCIAL OFFICER |
|
0 | 2007-10-01 | 0 |
|
SAFFERSTEIN HAROLD VP, BUSINESS DEVELOPMENT |
|
0 | 2007-06-19 | 0 |
|
7,000 | 2007-05-31 | 0 | |
|
BOKEL GEORG GENERAL MANAGER, GERMANY |
|
0 | 2007-03-28 | 0 |
|
BAB BIO VENTURES LLP MPM ASSET MANAGEMENT INVESTORS 1998 LLC MPM BIOVENTURES PARALLEL FUND L P MPM BIO VENTURES I LLC |
|
0 | 2006-11-02 | 0 |
|
28,730 | 2006-11-02 | 0 | |
|
60,640 | 2006-11-02 | 0 | |
|
58,884 | 2006-11-02 | 0 | |
|
0 | 2006-10-26 | 0 | |
|
21,909 | 2006-06-27 | 0 | |
|
BAB BIO VENTURES LLP MPM ASSET MANAGEMENT INVESTORS 1998 LLC MPM BIOVENTURES PARALLEL FUND L P MPM BIO VENTURES I LLC |
|
3,167,821 | 2006-04-11 | 0 |
|
MEDICAL PORTFOLIO MANAGEMENT LLC |
|
3,167,821 | 2006-04-11 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
